Adrian Mendes, the CEO of Perimeter Medical Imaging, recently shared some significant updates with Steve Darling from Proactive regarding the company's ongoing clinical trial efforts. Perimeter Medical Imaging has initiated an additional clinical trial site at the University of Washington in the Fred Hutch Cancer Center, situated in Seattle, Washington. Perimeter's clinical trial is a multi-center, randomized, two-arm pivotal study that evaluates the investigational Perimeter B-Series Optical Coherence Tomography (OCT) technology. This technology is combined with Perimeter's proprietary ImgAssist AI software and is used during breast conservation surgeries.
The core of this innovative approach is the use of ultra-high-resolution, real-time, advanced imaging tools to examine excised tissues at the cellular level, providing crucial insights to surgeons. Mendes emphasized the significance of this additional clinical trial site, as it plays a vital role in gathering valuable data generated during the study. This data will be instrumental in supporting the commercialization of Perimeter's B-Series technology.
The company's ultimate goal is to transform cancer surgery by providing advanced technology that not only improves patient outcomes but also helps reduce healthcare costs. In summary, Perimeter Medical Imaging, under the leadership of CEO Adrian Mendes, is making significant strides in advancing their groundbreaking technology for breast conservation surgeries. The expansion of clinical trial sites, including the addition of the Fred Hutch Cancer Center, underscores the company's commitment to gathering crucial data to support the commercialization of their innovative B-Series OCT technology. This technology has the potential to revolutionize cancer surgery and improve patient care.